Prostate Cancer

For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

Men with castration-sensitive prostate cancer now have an option for when treatment with androgen deprivation therapy alone is not enough.

A phase 3 trial showed a 33% reduction in the risk of death when patients were treated with Erleada compared with placebo.

I encourage men to be more knowledgeable of their family history and to potentially begin testing for prostate cancer earlier if you have a family history of the disease.

Here is a list of the recent trial initiations that occurred within the cancer space in August.

Following the Food and Drug Administration’s approval of Nubeqa, men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.

The Food and Drug Administration granted a priority review to Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer.

From today’s top performers and athletes to surprising findings about prostate cancer treatment, here’s what is making headlines in the cancer space this week.

One patient and a physician expert discuss a variety of topics in prostate cancer.

From Beth Chapman’s untimely passing to cancer fundraising via esports, here’s what is making headlines in the cancer space this week.

This essay was written by Dr. Kevin Yiee, CHI Health St. Elizabeth, nominating registered oncology-certified nurse Robin Devries for CURE®’s 2019 Extraordinary Healer® Award.

Thousands of men who will be diagnosed with prostate cancer this year alone now have a wealth of new and updated resources to ensure they make the best treatment choices they can.

A good nurse can make a huge difference for a patient struggling to deal with an illness, not only in comfort, or pain relief, or even in teaching how to manage symptoms or side effects – but in hope and confidence.

The Prostate Cancer Foundation announced the newly revised 2019 Prostate Cancer Patient Guide, a comprehensive resource for diagnosis, treatment, side effects, survivorship, and risk factors for patients and families with a history of prostate cancer.

The FDA has granted a priority review designation to a new drug application (NDA) for darolutamide for use as a treatment for patients with nonmetastatic castration-resistant prostate cancer.

Being a caregiver and survivor takes adjusting to the diagnosis of the "C" word. Until there is a cure for cancer, may we all do our best to put one breath and foot in front of another.

A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.